Nacre Capital

Nacre Capital is a venture builder that creates, builds and grows deep-technology startups from new ideas. Its stated process covers identifying fundamental needs, recruiting teams, providing financial, business development and legal support, and then ongoing financial, legal and recruiting support and market access.

The website describes an in-house portfolio that includes FDNA (digital health and AI for rare disease), Fairtility (AI-based IVF embryo selection), CureSign, Seed-X, Aquaticode, Kinsame, EveryWatch, DNA1 and MutualArt, and lists CyberMDX as acquired by Forescout in 2022. The website does not state how Nacre earns revenue or who its customers are beyond the ventures it builds.

The website names Howard Morgan as Chairman and Moti Shniberg as founder, and reports 200+ academic papers, 500+ research collaborations and 140+ granted patents. Open roles include operations internships in Wervershoof, North Holland, and remote positions tied to portfolio companies such as EveryWatch and FDNA.

Product: Venture-building service that creates, builds and grows deep-technology startups, providing financial, business development, legal and recruiting support.